Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 4/20 | 0.52 |
| ▸ | MITF | O75030 | 1/20 | 0.42 |
| ▸ | ALPG | P10696 | 2/20 | 0.41 |
| ▸ | PLAA | Q9Y263 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ALPL | P05186 | 1/20 | 0.40 |
| ▸ | GSK3A | P49840 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17889253 | 0.89 | ESR1 (0.45) | FPR2ESR1SMN1; SMN2 | |
| SCHEMBL21539521 | 0.88 | FPR2 (0.54) | FPR2MITFALPGPLAAALPL | |
| SCHEMBL2825741 | 0.85 | FPR2 (0.56) | FPR2MITFALPGPLAAALDH1A1 | |
| SCHEMBL16607258 | 0.84 | FPR2 (0.43) | FPR2ALPGPLAASMN1; SMN2ALPL | |
| SCHEMBL20068591 | 0.84 | FPR2 (0.47) | FPR2ALDH1A1KDM4E | |
| SCHEMBL21167198 | 0.83 | FPR2 (0.50) | FPR2MITFALPGPLAAALDH1A1 | |
| SCHEMBL368204 | 0.79 | POLB (0.51) | FPR2MITFALPGPLAAALDH1A1 | |
| SCHEMBL18839857 | 0.78 | FPR2 (0.46) | FPR2MITFALPGPLAAALPL | |
| SCHEMBL7868637 | 0.78 | HSP90AA1 (0.52) | SMN1; SMN2 | |
| SCHEMBL16607272 | 0.77 | FPR2 (0.41) | FPR2MITFALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3511003-B1 | CYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | TORAY INDUSTRIES (JP) | 2021-03-03 | — | — | EP | disclosed |
| EP-3511003-B1 | CYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | TORAY INDUSTRIES (JP) | 2021-03-03 | — | — | EP | disclosed |
| EP-3511002-B1 | CYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | TORAY INDUSTRIES (JP) | 2020-08-19 | — | — | EP | disclosed |
| EP-3511002-B1 | CYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | TORAY INDUSTRIES (JP) | 2020-08-19 | — | — | EP | disclosed |
| CN-107207462-B | Cyclic amine derivative and medical use thereof | 东丽株式会社 | 2020-03-06 | — | — | CN | disclosed |
| EP-3050877-B1 | CYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | TORAY INDUSTRIES (JP) | 2019-10-30 | — | — | EP | disclosed |
| EP-3050877-B1 | CYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | TORAY INDUSTRIES (JP) | 2019-10-30 | — | — | EP | disclosed |
| EP-3511003-A1 | CYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | Toray Industries, Inc. (JP) | 2019-07-17 | — | — | EP | disclosed |
| EP-3511002-A1 | CYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | Toray Industries, Inc. (JP) | 2019-07-17 | — | — | EP | disclosed |
| EP-3511003-A1 | CYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | Toray Industries, Inc. (JP) | 2019-07-17 | — | — | EP | disclosed |
| EP-3275879-A1 | CYCLIC AMINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | Toray Industries, Inc. (JP) | 2018-01-31 | — | — | EP | disclosed |
| US-9505740-B2 | Cyclic amine derivative and pharmaceutical use thereof | TORAY INDUSTRIES, INC. | 2016-11-29 | — | — | US | disclosed |
| US-9505740-B2 | Cyclic amine derivative and pharmaceutical use thereof | TORAY INDUSTRIES, INC. | 2016-11-29 | — | — | US | disclosed |
| US-9505740-B2 | Cyclic amine derivative and pharmaceutical use thereof | TORAY INDUSTRIES, INC. | 2016-11-29 | — | — | US | disclosed |
| WO-2016152955-A1 | CYCLIC AMINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | 東レ株式会社 | 2016-09-29 | — | — | WO | disclosed |
| EP-3050877-A1 | CYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | Toray Industries, Inc. (JP) | 2016-08-03 | — | — | EP | disclosed |
| US-20160194302-A1 | CYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | TORAY INDUSTRIES, INC. (JP) | 2016-07-07 | — | — | US | disclosed |
| US-20160194302-A1 | CYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | TORAY INDUSTRIES, INC. (JP) | 2016-07-07 | — | — | US | disclosed |
| US-20160194302-A1 | CYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | TORAY INDUSTRIES, INC. (JP) | 2016-07-07 | — | — | US | disclosed |
| WO-2015046403-A1 | CYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | 東レ株式会社 | 2015-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160194302-A1 | CYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | CNR2, OPRL1, CNR1 | FPR2 149/4885MITF 3898/4885ALPG 4682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.